On the fly News and insights, exclusive to thefly.com

PFE

Pfizer

$42.82 /

+0.01 (+0.02%)

14:34
07/30/21
07/30
14:34
07/30/21
14:34

FDA to accelerate review of Pfizer Covid vaccine, STAT reports

The Food and Drug Administration is planning to deprioritize some of its existing work in an effort to accelerate its review of Pfizer's application for the formal approval of its Covid-19 vaccine, a senior agency official told STAT, reports Nicholas Florko. The process requires FDA staff to review millions of pages of data, conduct plant inspections, and negotiate with Pfizer over issues including the terms of the FDA's approved label and the company's post-marketing responsibilities, notes Florko. A senior FDA official told STAT that the agency will initiate a "sprint." Under a new plan, the director of FDA's biologics center, Peter Marks, will largely oversee review of the Pfizer application, a second FDA source told the website. Reference Link

  • 30

    Jul

  • 10

    Aug

  • 16

    Sep

  • 16

    Sep

  • 29

    Dec

PFE Pfizer
$42.82 /

+0.01 (+0.02%)

07/30/21 Mizuho
Pfizer price target raised to $43 from $42 at Mizuho
07/26/21 Truist
Pfizer assumed with a Buy at Truist
07/26/21 Truist
Pfizer assumed with a Buy at Truist
07/23/21 BMO Capital
Arvinas price target raised to $111 from $101 at BMO Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.